In Subgroups of NMOSD, Ravulizumab is Superior at Preventing On-Trial Relapse.

Published Date: 04 May 2023

In the CHAMPION-NMOSD trial, the therapy was more effective than placebo at preventing on-trial relapse in the immunosuppressive therapy and monotherapy groups.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

4.

The pandemic had little impact on mental health symptoms.

5.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot